# Study With Various Immunotherapy Treatments in Participants With Lung Cancer

> **NCT05676931** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Gilead Sciences** · enrollment: 400 (estimated)

## Conditions studied

- Advanced Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Domvanalimab
- **DRUG:** Quemliclustat
- **DRUG:** Zimberelimab
- **DRUG:** Docetaxel
- **DRUG:** Platinum-Based Doublet

## Key facts

- **NCT ID:** NCT05676931
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-02-21
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2025-10-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05676931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05676931, "Study With Various Immunotherapy Treatments in Participants With Lung Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05676931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*